atopic dermatitis
Lilly’s Olumiant impresses in twin Phase 3 atopic dermatitis trials
February 5, 2019Manufacturing and Production, Research and Development Eli Lilly, Olumiant, atopic dermatitis, pharma
Eli Lilly has unveiled new Phase 3 data from two studies into the oral Janus kinase (JAK) inhibitor Olumiant (baricitinib). …
Atopic dermatitis market set to almost triple in value over next 10 years
December 12, 2018Research and Development atopic dermatitis, eczema, global data, markets, money
The atopic dermatitis (eczema) market is expected to reach $18.3 billion by 2027, according to analytics firm GlobalData. The market …
Sanofi’s Dupixent improves symptoms for adolescent atopic dermatitis patients
September 17, 2018Research and Development, Sales and Marketing Dupixent, EADV 2018, Sanofi, atopic dermatitis, pharma
Sanofi’s Dupixent (dupilumab) has made a strong showing as a monotherapy at Phase 3 in the treatment of moderate-to-severe atopic …
Realm Therapeutics shares halved after failure of Phase 2 study
August 15, 2018Research and Development London, Shares, atopic dermatitis, phase 2, stock market
Shares in the London-listed Realm Therapeutics plummeted on Monday after the company reported that a Phase II study of the …
NICE backs Sanofi’s new treatment for atopic dermatitis
June 22, 2018Medical Communications, Sales and Marketing England, NICE, Sanofi, UK, atopic dermatitis, pharma
NICE has published a positive Final Appraisal Determination FAD recommending dupilumab, in combination with topical corticosteroids, for use on the …
NICE rejects Dupixent for atopic dermatitis on cost grounds, Sanofi responds
April 4, 2018Research and Development, Sales and Marketing Dupixent, NICE, Sanofi, atopic dermatitis, eczema, pharma
UK drug watchdog NCIE has issued draft guidance rejecting the routine use of Sanofi’s Dupixent (dupilumab) for the treatment of …
FDA approves first-ever atopic dermatitis biologic treatment
March 31, 2017Medical Communications, Sales and Marketing Dupixent, Regeneron, Sanofi, atopic dermatitis, biologic
Sanofi and Regeneron’s Dupixent (dupilumab) has become the first biologic medicine to be approved by the FDA for the treatment …
Pfizer’s next blockbuster given FDA approval
December 15, 2016Business Services, Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing Pfizer, atopic dermatitis, eczema
Pfizer announced that it had received approval for its eczema treatment, Eucrisa, for patients of two years of age and …
Pfizer announces strong Phase III results for atopic dermatitis drug
July 14, 2016Research and Development Pfizer, anacor, atopic dermatitis, crisaborole, eczema
Pfizer (NYSE: PFE) has announced positive results from two pivotal Phase III studies for crisaborole in the treatment of mild …
Sanofi and Regeneron combo shows superiority in late-stage atopic dermatitis trials
June 6, 2016Research and Development, Sales and Marketing Dupilumab, Regeneron, Sanofi, atopic dermatitis, late stage trials
Sanofi (NYSE: SNY) and Regeneron (NASDAQ: REGN) have announced positive results from a Phase III trial evaluating dupilumab in patients …
Sanofi and Regeneron announce positive Phase III trial results for chronic skin disease treatment
April 1, 2016Medical Communications, Research and Development Dupilumab, Regeneron, Sanofi, atopic dermatitis, phase III, skin disease
Sanofi (NYSE: SNY) and Regeneron Pharmaceuticals (NASDAQ: REGN) have announced positive top line results for dupilumab in Phase III clinical …
Latest content
Global coalition calls for stronger government action on COPD
Global health researchers call for more equitable partnerships
Liverpool launches £20m lab for infectious disease drug discovery
Circle Health Group expands into UK laboratory operations
FibroFind appoints Professor Andrew Fisher as Chief Medical Officer
